1 report

  • APR 20, 2017: ORAL PRESENTATION AT EASL HIGHLIGHTS CONTRAVIR'S TENOFOVIR EXALIDEX ANTIVIRAL ACTIVITY IN HEPATITIS B PATIENTS
  • OCT 24, 2017: CONTRAVIR PHARMACEUTICALS ANNOUNCES NATIONAL INSTITUTES OF HEALTH FUNDED STUDY ON ANTIVIRAL ACTIVITY OF CRV431

One oral presentation, and one poster presentation, will disclose the most recent findings on the company' s novel drug TXL, for the treatment of chronic hepatitis B.

  • Antiviral
  • Pharmaceutical
  • United States
  • Company
  • ContraVir Pharmaceuticals, Inc.